Suresh Ramalingam outlines the key findings from the 3-year update of the CheckMate 227 trial of first-line nivolumab and ipilimumab in advanced non-small-cell lung cancer (6:50).
31-05-2020 | ASCO 2020 | Conference coverage | Video
31-05-2020 | ASCO 2020 | Conference coverage | Video
Suresh Ramalingam outlines the key findings from the 3-year update of the CheckMate 227 trial of first-line nivolumab and ipilimumab in advanced non-small-cell lung cancer (6:50).